

2 March 2017

PureTech Health plc

**PureTech Health Appoints Bharatt Chowrira, Ph.D., J.D., as President and Chief of Business and Strategy**

*Biopharmaceutical veteran brings strong track record of value realisation with multiple billion dollar deals and collaborations*

PureTech Health plc (“PureTech” or the “Company”, LSE: PRTC), a cross-disciplinary biopharmaceutical company, today announced the appointment of Bharatt Chowrira, Ph.D., J.D., as the Company’s President and Chief of Business and Strategy. In this new role, Dr. Chowrira will work as a close partner to PureTech’s Chief Executive on strategy, corporate and business development, and value realisation across PureTech Health’s pipeline.

“We are thrilled to have Bharatt join PureTech Health and bring his diverse experience and deal-making track record to our team as we rapidly approach key value-driving milestones,” said Daphne Zohar, Chief Executive Officer of PureTech Health.

“PureTech Health has an all-star team and an exciting, advanced pipeline which I believe has tremendous value. I look forward to working closely with Daphne and other members of this exceptional team and prestigious board to realise some of this value and raise the profile of the company with a broader group of investors and analysts. This is an exciting time to join one of the most innovative companies in healthcare and biotech,” Dr. Chowrira commented.

Dr. Chowrira joins PureTech health with more than two decades of experience in the biopharma industry, combining a unique blend of R&D, corporate development, operations, financing, public offering, M&A, legal, IP, and licensing expertise. Dr. Chowrira was most recently the President of Synlogic, a Cambridge, MA-based biopharmaceutical company focused on developing synthetic microbiome-based therapeutics, where he oversaw and managed corporate and business development, alliance management, financial, HR, IP, and legal operations. Prior to joining Synlogic, Dr. Chowrira was the Chief Operating Officer of Auspex Pharmaceuticals, which was acquired by Teva Pharmaceuticals in the spring of 2015 for \$3.5 billion. Previously, he was President and Chief Executive Officer of Addex Therapeutics, a biotechnology company publicly-traded on the SIX Swiss Exchange. Before that, he held various leadership and management positions at Nektar Therapeutics, Merck & Co., Sirna Therapeutics, (acquired by Merck & Co. for \$1.1 billion) and Ribozyme Pharmaceuticals. Dr. Chowrira has a J.D. from the University of Denver’s Sturm College of Law, a Ph.D. in Molecular Biology from the University of Vermont College of Medicine, an M.S. in Molecular Biology from Illinois State University, and a B.S. in Microbiology from the UAS, Bangalore, India.

**About PureTech Health**

[PureTech Health](#) (PureTech Health plc, PRTC.L) is a cross-disciplinary biopharmaceutical company creating 21<sup>st</sup> century medicines that modulate the adaptive human systems. Our therapies target the immune,



nervous, and gastro-intestinal systems by addressing the underlying pathophysiology of disease from a systems perspective rather than through a single receptor or pathway. We have multiple human proof-of-concept studies and pivotal or registration studies expected to read out in the next two years. PureTech Health's rich and growing research and development pipeline has been developed in collaboration with some of the world's leading scientific experts who, along with PureTech's experienced team and board, analyse more than 650 scientific discoveries per year to identify and advance only the opportunities we believe hold the most promise for patients. This team and process place PureTech Health on the cutting edge of ground-breaking science and technological innovation and leads the Company between and beyond existing disciplines. For more information, visit [www.puretechhealth.com](http://www.puretechhealth.com) or connect with us on [Twitter](#).

### **Forward Looking Statement**

This press release contains statements that are or may be forward-looking statements, including statements that relate to the company's future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in the regulatory filings for PureTech Health plc. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

### **For further information:**

#### **PureTech Health**

Allison Mead  
+1 617 651 3156  
[amead@puretechhealth.com](mailto:amead@puretechhealth.com)

#### **FTI Consulting**

Ben Atwell  
+44 (0) 20 3727 1000